Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

Francesco Massari, Chiara Ciccarese, Matteo Santoni, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Liang Cheng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

Original languageEnglish (US)
Pages (from-to)1367-1369
Number of pages3
JournalExpert Review of Anticancer Therapy
Volume15
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Fibroblast Growth Factor Receptors
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Therapeutics

Keywords

  • fibroblast growth factor receptor
  • kidney
  • personalized medicine
  • precision medicine
  • renal cell carcinoma
  • targeted therapy
  • vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Massari, F., Ciccarese, C., Santoni, M., Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Cheng, L. (2015). Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy, 15(12), 1367-1369. https://doi.org/10.1586/14737140.2015.1110488

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. / Massari, Francesco; Ciccarese, Chiara; Santoni, Matteo; Lopez-Beltran, Antonio; Scarpelli, Marina; Montironi, Rodolfo; Cheng, Liang.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 12, 02.12.2015, p. 1367-1369.

Research output: Contribution to journalArticle

Massari, F, Ciccarese, C, Santoni, M, Lopez-Beltran, A, Scarpelli, M, Montironi, R & Cheng, L 2015, 'Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma', Expert Review of Anticancer Therapy, vol. 15, no. 12, pp. 1367-1369. https://doi.org/10.1586/14737140.2015.1110488
Massari F, Ciccarese C, Santoni M, Lopez-Beltran A, Scarpelli M, Montironi R et al. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy. 2015 Dec 2;15(12):1367-1369. https://doi.org/10.1586/14737140.2015.1110488
Massari, Francesco ; Ciccarese, Chiara ; Santoni, Matteo ; Lopez-Beltran, Antonio ; Scarpelli, Marina ; Montironi, Rodolfo ; Cheng, Liang. / Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. In: Expert Review of Anticancer Therapy. 2015 ; Vol. 15, No. 12. pp. 1367-1369.
@article{53906520bf2848ef9f9d9b4b91bfe0fb,
title = "Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma",
abstract = "Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.",
keywords = "fibroblast growth factor receptor, kidney, personalized medicine, precision medicine, renal cell carcinoma, targeted therapy, vascular endothelial growth factor receptor",
author = "Francesco Massari and Chiara Ciccarese and Matteo Santoni and Antonio Lopez-Beltran and Marina Scarpelli and Rodolfo Montironi and Liang Cheng",
year = "2015",
month = "12",
day = "2",
doi = "10.1586/14737140.2015.1110488",
language = "English (US)",
volume = "15",
pages = "1367--1369",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma

AU - Massari, Francesco

AU - Ciccarese, Chiara

AU - Santoni, Matteo

AU - Lopez-Beltran, Antonio

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

AU - Cheng, Liang

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

AB - Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.

KW - fibroblast growth factor receptor

KW - kidney

KW - personalized medicine

KW - precision medicine

KW - renal cell carcinoma

KW - targeted therapy

KW - vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84949315067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949315067&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1110488

DO - 10.1586/14737140.2015.1110488

M3 - Article

VL - 15

SP - 1367

EP - 1369

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -